Orchestra BioMed Holdings, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
OBIO Nasdaq 3840 orchestrabiomed.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Orchestra BioMed Holdings, Inc.

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025 - Jun 18th, 2025 7:30 am
Sidoti Events, LLC's Virtual May Micro-Cap Conference - May 20th, 2025 6:00 am
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates - May 12th, 2025 3:40 pm
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones - May 12th, 2025 2:28 pm
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure - May 7th, 2025 6:30 am
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates - May 6th, 2025 3:10 pm
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - May 5th, 2025 8:00 am
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon - Apr 29th, 2025 7:00 am
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - Apr 28th, 2025 2:30 pm
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting - Apr 23rd, 2025 7:00 am
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy - Apr 22nd, 2025 5:00 am
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates - Mar 31st, 2025 5:05 pm
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update - Mar 31st, 2025 2:21 pm
Freightos And 2 Other Penny Stocks Worth Watching - Mar 24th, 2025 11:05 am
Orchestra BioMed to Present at Upcoming Investor Conferences - Feb 20th, 2025 6:00 am
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board - Feb 18th, 2025 6:00 am
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference - Feb 12th, 2025 8:43 am
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors - Feb 5th, 2025 6:00 am
US Penny Stocks Spotlight: AC Immune And Two Others To Consider - Jan 2nd, 2025 5:07 pm
Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) top owners are individual investors with 26% stake, while 22% is held by hedge funds - Dec 25th, 2024 3:07 am